Related Experiment Video
Updated: Jul 16, 2025

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
Pantoprazole-Induced Bone Loss through Gastrin Secretion: A Stereological Study
Forough Saki1, Mesbah Shams1, Sanaz Dastghaib1
1Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Pantoprazole causes bone loss by increasing gastrin secretion, a condition that can be prevented by octreotide. This study investigated the link between pantoprazole, gastrin, and bone density in rats.
Area of Science:
- Endocrinology
- Bone Biology
- Pharmacology
Background:
- Proton pump inhibitors (PPIs) are linked to bone loss, but the mechanism remains unclear.
- Pantoprazole's effect on gastrin secretion suggests a potential pathway for bone loss.
Purpose of the Study:
- To investigate if pantoprazole induces bone loss via gastrin secretion.
- To determine the efficacy of octreotide in preventing pantoprazole-induced bone loss.
Main Methods:
- Forty male rats were divided into four groups: control, octreotide, pantoprazole, and pantoprazole plus octreotide.
- Biochemical markers (calcium, phosphorous, alkaline phosphatase, PTH, gastrin) and bone densitometry were measured.
- Femoral bone structure was stereologically analyzed.
Main Results:
- Pantoprazole significantly increased alkaline phosphatase, PTH, and gastrin levels, which octreotide counteracted.
- Bone densitometry revealed significant bone loss in the pantoprazole group, mitigated by octreotide.
- Pantoprazole reduced trabecular bone volume and femur bone weight, increased osteoclast count, and decreased osteocyte number.
Conclusions:
- Pantoprazole induces bone loss, likely mediated by hypergastrinemia.
- Octreotide effectively prevents pantoprazole-induced bone loss, supporting the role of gastrin.
Related Concept Videos
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...

